BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu Sells 4,500 Shares

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 4,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total transaction of $900,630.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, September 17th, Xiaobin Wu sold 500 shares of BeiGene stock. The stock was sold at an average price of $200.00, for a total transaction of $100,000.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Price Performance

Shares of BeiGene stock opened at $198.59 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. The company has a market cap of $19.24 billion, a PE ratio of -26.23 and a beta of 0.61. The firm has a fifty day moving average price of $181.25 and a two-hundred day moving average price of $164.21. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $215.00.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. During the same quarter last year, the company earned ($3.64) earnings per share. The firm’s revenue was up 56.1% on a year-over-year basis. Analysts expect that BeiGene, Ltd. will post -5.13 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Citigroup boosted their target price on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. JMP Securities initiated coverage on shares of BeiGene in a research note on Wednesday. They issued a “market outperform” rating and a $288.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, Bank of America lowered their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, BeiGene has a consensus rating of “Moderate Buy” and a consensus target price of $241.21.

Institutional Trading of BeiGene

A number of hedge funds have recently modified their holdings of BGNE. Headlands Technologies LLC acquired a new stake in shares of BeiGene during the 1st quarter valued at about $50,000. Benjamin F. Edwards & Company Inc. boosted its holdings in BeiGene by 51.5% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after purchasing an additional 279 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of BeiGene in the 4th quarter valued at approximately $183,000. Acadian Asset Management LLC raised its holdings in shares of BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after buying an additional 849 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. bought a new position in shares of BeiGene during the 1st quarter worth approximately $209,000. Institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.